Pfizer registers Q4FY21net profit at Rs 100 Cr
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
This marks Glenmark's first synthetic decapeptide injectable approval
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
The company plans to enter the EU markets in FY22
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
NATCO and Arrow shall launch the product on agreed-upon launch dates in the future.
Subscribe To Our Newsletter & Stay Updated